Cetuximab for Elderly Patients With mCRC

- The folks at Swiss Group for Clinical Cancer Research are studying the effects of Cetuximab; Capecitabine on Metastatic Colorectal Cancer in individuals ages 70 years and older. This clinical trial is slated to start November 2012 and is expected to end circa December 2017.

+41 31 389 94 64
Scarlett Keunecke
Overall Study Contact Info
StatusName Contact Phone
RecruitingScarlett Keuneckescarlett.keunecke@sakk.ch+41 31 389 94 64

This study is officially titled, "Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial."

Locations

UniversitaetsSpital Zuerich

Zurich, Switzerland - Recruiting

Klinik Hirslanden

Zurich, Switzerland - Recruiting

Kantonsspital Winterthur

Winterthur, Switzerland - Recruiting

SpitalSTS AG Simmental-Thun-Saanenland

Thun, Switzerland - Recruiting

Kantonsspital - St. Gallen

St. Gallen, Switzerland - Recruiting

Kantonsspital Muensterlingen

Muensterlingen, Switzerland - Recruiting

Kantonsspital Luzern

Luzern, Switzerland - Recruiting

Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland - Recruiting

Hopital Cantonal Universitaire de Geneve

Geneva, Switzerland - Recruiting

Hopital Fribourgeois

Fribourg, Switzerland - Recruiting

Spitalzentrum Biel

Biel, Switzerland - Recruiting

Inselspital, Bern

Bern, Switzerland - Recruiting

Universitaetsspital-Basel

Basel, Switzerland - Recruiting

Stadtspital Triemli

Zrich, Switzerland - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.